Science World ReportFDA Rejects Novel Novartis Drug For Acute Heart FailureForbesNovartis Novartis said today that the FDA had issued a complete response letter for the biologics license application for RLX030. The drug, also known as serelaxin, is a recombinant form of the naturally occurring human hormone relaxin-2, which has been …FDA Rejects Novartis’ Heart Failure Drug–AgainScience World ReportFDA Rejects Novartis’ SerelaxinGenetic Engineering NewsFDA does not approve serelaxin for treatment of acute HFHealioGlobalPost -FierceBiotechall 18 news articles …Read Full Story
FDA Rejects Novel Novartis Drug For Acute Heart Failure - Forbes
Real Estate of Cebu
